The FDA has approved an all-oral, two-drug combination from Eli Lilly — Inluriyo (imlunestrant) plus Verzenio (abemaciclib) — for a specific, hard-to-treat form of advanced breast cancer, after a trial showed it doubled the time the cancer stayed under control.

The cancer it targets

The approval (granted September 18, 2026) is for adults with ER-positive, HER2-negative breast cancer — the most common subtype, fueled by the hormone estrogen — that is locally advanced or metastatic, carries an ESR1 mutation, and has progressed after at least one line of endocrine (hormone) therapy. That ESR1 detail is central: ESR1 mutations are a common way these cancers become resistant to standard hormone treatments like aromatase inhibitors, so patients whose disease develops them need a different approach.

How the combination works

The two drugs hit two central drivers of this cancer at once. Imlunestrant is an oral SERD (selective estrogen receptor degrader) — it tags the estrogen receptor for destruction, shutting down the estrogen signaling that drives tumor growth even in the presence of ESR1 mutations. Abemaciclib is a CDK4/6 inhibitor, blocking the machinery cancer cells use to divide. Together, the all-oral regimen attacks the tumor from two directions, with what Lilly describes as an established tolerability profile and no new monitoring required.

The evidence

Approval was based on the Phase 3 EMBER-3 trial. The key result: for patients whose cancer had progressed, switching to imlunestrant plus abemaciclib doubled median progression-free survival to 11.1 months, compared with 5.5 months on imlunestrant alone. Progression-free survival measures how long patients live without their cancer worsening — so doubling it means meaningfully more time before the disease advances. The FDA also approved the Guardant360 CDx blood test as a companion diagnostic to identify patients with ESR1 mutations who qualify.

The bigger picture

This is imlunestrant’s second FDA approval in under a year — it was first cleared in September 2025 as a single agent for the same ESR1-mutated setting. The new combination approval reflects a broader shift in breast-cancer care toward oral SERDs as a way to overcome ESR1-driven resistance, and toward biomarker-guided treatment, where a blood test (rather than a new biopsy) matches patients to the right drug. It’s part of the same wave that has several oral SERDs competing to become the go-to option after first-line therapy fails.

Why it matters — and the caveat

For patients whose breast cancer has grown resistant to standard hormone therapy, an all-oral combination that roughly doubles progression-free time — without new monitoring burdens or an infusion chair — is a practical, meaningful option. The caveat, as always, is that progression-free survival is not the same as overall survival, and individual results vary; the right regimen depends on a patient’s specific tumor and history, decided with an oncologist. This is regulatory news, not medical advice.